000142489 001__ 142489
000142489 005__ 20240229105148.0
000142489 0247_ $$2doi$$a10.1080/2162402X.2018.1428157
000142489 0247_ $$2pmid$$apmid:29872552
000142489 0247_ $$2pmc$$apmc:PMC5980408
000142489 0247_ $$2ISSN$$a2162-4011
000142489 0247_ $$2ISSN$$a2162-402X
000142489 0247_ $$2altmetric$$aaltmetric:32214387
000142489 037__ $$aDKFZ-2019-00208
000142489 041__ $$aeng
000142489 082__ $$a610
000142489 1001_ $$aMichels, Judith$$b0
000142489 245__ $$aMultiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial.
000142489 260__ $$aAbingdon$$bTaylor & Franics$$c2018
000142489 3367_ $$2DRIVER$$aarticle
000142489 3367_ $$2DataCite$$aOutput Types/Journal article
000142489 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1680684091_11713
000142489 3367_ $$2BibTeX$$aARTICLE
000142489 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142489 3367_ $$00$$2EndNote$$aJournal Article
000142489 520__ $$aPurpose: Determine the prognostic and predictive significance of tumor associated antigen (TAA)-specific serum antibodies in melanoma patients of a large adjuvant vaccination phase III trial. Patients and methods: Serum IgG antibodies were measured against a panel of 43 antigens by a bead-based multiplex assay in 970 stage II melanoma patients of the EORTC18961 trial, evaluating adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation. Primary end point was relapse-free survival (RFS). Patients' sera at baseline, after 12 and 48 weeks of study treatment and at the last available time point (at recurrence/remission) were evaluated. Results: Prognostic clinical variables are gender, surgical confirmation of lymph node-negative status, Breslow thickness and ulceration of the primary. Prognostic spontaneous antibody responses were associated with a significant dismal (GM2, Rhod_E2, SSX2) or good prognosis (CyclinB1, SCYE1v1) for RFS, distant metastasis-free (DMFS) or overall survival (OS). Predictive spontaneous antibody responses based on significant interaction with treatment were RhodN p = 0.02, Rab38 p = 0.04 for RFS, RhodE2 p = 0.006, Recoverin p = 0.04 for DMFS and RhodE2 p = 0.003; Recoverin p = 0.04, NA17.A p = 0.04, for OS respectively. The subgroups of patients according to antibody responses for RFS were determined for RhodN sero-negative (n = 849, HR = 1.07, p = 0.6); RhodN sero-positive (n = 121,HR = 0.42, p = 0.01) and Rab38 sero-negative (n = 682, HR = 1.12, p = 0.42), Rab38 sero-positive (n = 288, HR = 0.65, p = 0.04) patients respectively. Conclusion: We identified prognostic serum antibody responses against TAA in stage II melanoma patients. A set of antibody responses correlated with a beneficial outcome for GM2 vaccination.
000142489 536__ $$0G:(DE-HGF)POF3-314$$a314 - Tumor immunology (POF3-314)$$cPOF3-314$$fPOF III$$x0
000142489 588__ $$aDataset connected to CrossRef, PubMed,
000142489 7001_ $$aBecker, Natalia$$b1
000142489 7001_ $$aSuciu, Stefan$$b2
000142489 7001_ $$0P:(DE-He78)b532cde04c20e4a2ce7edc5154f60cec$$aKaiser, Iris$$b3
000142489 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b4
000142489 7001_ $$aKosaloglu-Yalcin, Zeynep$$b5
000142489 7001_ $$aAgoussi, Sandrine$$b6
000142489 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b7
000142489 7001_ $$0P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aPawlita, Michael$$b8
000142489 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b9
000142489 7001_ $$0P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aEichmüller, Stefan$$b10
000142489 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b11
000142489 7001_ $$aEggermont, Alexander M M$$b12
000142489 7001_ $$0P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3$$aZörnig, Inka$$b13
000142489 773__ $$0PERI:(DE-600)2645309-5$$a10.1080/2162402X.2018.1428157$$gVol. 7, no. 6, p. e1428157 -$$n6$$pe1428157 -$$tOncoImmunology$$v7$$x2162-402X$$y2018
000142489 909CO $$ooai:inrepo02.dkfz.de:142489$$pVDB
000142489 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)b532cde04c20e4a2ce7edc5154f60cec$$aExternal Institute$$b3$$kExtern
000142489 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000142489 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aExternal Institute$$b7$$kExtern
000142489 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000142489 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000142489 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000142489 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000142489 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3$$aExternal Institute$$b13$$kExtern
000142489 9131_ $$0G:(DE-HGF)POF3-314$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTumor immunology$$x0
000142489 9141_ $$y2018
000142489 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOIMMUNOLOGY : 2017
000142489 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142489 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142489 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142489 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142489 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000142489 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000142489 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142489 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142489 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142489 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142489 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOIMMUNOLOGY : 2017
000142489 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000142489 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lD120 Angewandte Tumor-Immunität$$x1
000142489 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lInfektionen und Krebs-Epidemiologie$$x2
000142489 9201_ $$0I:(DE-He78)F022-20160331$$kF022$$lInfektionen und Krebs-Epidemiologie$$x3
000142489 9201_ $$0I:(DE-He78)G183-20160331$$kG183$$lPräklinische T-Zellforschung$$x4
000142489 9201_ $$0I:(DE-He78)G182-20160331$$kG182$$lGMP Einheit  Zelluläre Therapie$$x5
000142489 980__ $$ajournal
000142489 980__ $$aVDB
000142489 980__ $$aI:(DE-He78)C060-20160331
000142489 980__ $$aI:(DE-He78)D120-20160331
000142489 980__ $$aI:(DE-He78)F020-20160331
000142489 980__ $$aI:(DE-He78)F022-20160331
000142489 980__ $$aI:(DE-He78)G183-20160331
000142489 980__ $$aI:(DE-He78)G182-20160331
000142489 980__ $$aUNRESTRICTED